Skip to main navigation Skip to search Skip to main content

Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension

  • U.K. National Institute for Health Research BioResource Rare Diseases Consortium, U.K. Pulmonary Arterial Hypertension Cohort Study Consortium, and U.S. Pulmonary Arterial Hypertension Biobank Consortium
  • Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom; Centre for Neuropsychopharmacology and Computational, Cognitive and Clinical Neuroimaging Laboratory, Division of Brain Sciences, Department of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom...
  • Weston Park Hospital, Sheffield, UK; University of Sheffield, Sheffield, UK. Electronic address: [email protected].
  • College of Pharmacy, University of Arizona, Tucson, AZ, USA.
  • School of Public Health, Indiana University, Bloomington, Indiana, USA.
  • University of Cincinnati College of Medicine, Cincinnati, United States
  • Université Paris-Sud et Université Paris-Saclay, France
  • Justus Liebig University Giessen
  • University of Cambridge School of Clinical Medicine
  • Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin

Research output: Contribution to journalArticleAcademicpeer-review

17 Downloads (Pure)

Abstract

Rationale: Pulmonary arterial hypertension (PAH) is characterized by structural remodeling of pulmonary arteries and arterioles. Underlying biological processes are likely reflected in a perturbation of circulating proteins. Objectives: To quantify and analyze the plasma proteome of patients with PAH using inherited genetic variation to inform on underlying molecular drivers. Methods: An aptamer-based assay was used to measure plasma proteins in 357 patients with idiopathic or heritable PAH, 103 healthy volunteers, and 23 relatives of patients with PAH. In discovery and replication subgroups, the plasma proteomes of PAH and healthy individuals were compared, and the relationship to transplantation-free survival in PAH was determined. To examine causal relationships to PAH, protein quantitative trait loci (pQTL) that influenced protein levels in the patient population were used as instruments for Mendelian randomization (MR) analysis. Measurements and Main Results: From 4,152 annotated plasma proteins, levels of 208 differed between patients with PAH and healthy subjects, and 49 predicted long-term survival. MR based on cis-pQTL located in proximity to the encoding gene for proteins that were prognostic and distinguished PAH from health estimated an adverse effect for higher levels of netrin-4 (odds ratio [OR], 1.55; 95% confidence interval [CI], 1.16-2.08) and a protective effect for higher levels of thrombospondin-2 (OR, 0.83; 95% CI, 0.74-0.94) on PAH. Both proteins tracked the development of PAH in previously healthy relatives and changes in thrombospondin-2 associated with pulmonary arterial pressure at disease onset. Conclusions: Integrated analysis of the plasma proteome and genome implicates two secreted matrix-binding proteins, netrin-4 and thrombospondin-2, in the pathobiology of PAH.

Original languageEnglish
Pages (from-to)1449-1460
Number of pages12
JournalAmerican journal of respiratory and critical care medicine
Volume205
Issue number12
DOIs
Publication statusPublished - 15 Jun 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Mendelian randomization
  • case-control studies
  • genome
  • protein quantitative trait loci

Fingerprint

Dive into the research topics of 'Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension'. Together they form a unique fingerprint.

Cite this